
    
      The study will be conducted in two phases: dose escalation and expansion. Up to three dose
      levels of SBP-101 will be assessed in up to 18 subjects during dose escalation. The expansion
      phase of the study will consist of 10 additional subjects who will receive the recommended
      dose of SBP-101 combined with nab-paclitaxel and gemcitabine.
    
  